HOCPY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 22.37% compared to Hoya's net margin of -6742.11%. Hoya's return on equity of 20.47% beat Healios KK's return on equity of -196.15%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than Healios KK, analysts believe Hoya is more attractive than Healios KK.

Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hoya quarterly revenues are $1.5B, which are larger than Healios KK quarterly revenues of $249.2K. Hoya's net income of $331M is higher than Healios KK's net income of -$16.8M. Notably, Hoya's price-to-earnings ratio is 29.71x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.78x versus 76.64x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 22.37% compared to Hoya's net margin of -24.41%. Hoya's return on equity of 20.47% beat PeptiDream's return on equity of 34.1%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than PeptiDream, analysts believe Hoya is more attractive than PeptiDream.

Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hoya quarterly revenues are $1.5B, which are larger than PeptiDream quarterly revenues of $27.8M. Hoya's net income of $331M is higher than PeptiDream's net income of -$6.8M. Notably, Hoya's price-to-earnings ratio is 29.71x while PeptiDream's PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.78x versus 4.76x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 22.37% compared to Hoya's net margin of -11.44%. Hoya's return on equity of 20.47% beat Nxera Pharma's return on equity of -8.65%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Hoya has higher upside potential than Nxera Pharma, analysts believe Hoya is more attractive than Nxera Pharma.

Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hoya pays 19.01% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hoya quarterly revenues are $1.5B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Hoya's net income of $331M is higher than Nxera Pharma's net income of -$5M. Notably, Hoya's price-to-earnings ratio is 29.71x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.78x versus 3.51x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 22.37% compared to Hoya's net margin of -9.79%. Hoya's return on equity of 20.47% beat Takeda Pharmaceutical's return on equity of 1.49%.

Hoya has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 17.03%. Given that Takeda Pharmaceutical has higher upside potential than Hoya, analysts believe Takeda Pharmaceutical is more attractive than Hoya.

Hoya has a beta of 0.911, which suggesting that the stock is 8.893% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

Hoya has a quarterly dividend of $0.80 per share corresponding to a yield of 0.96%. Takeda Pharmaceutical offers a yield of 4.19% to investors and pays a quarterly dividend of $0.33 per share. Hoya pays 19.01% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Hoya's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Hoya quarterly revenues are $1.5B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Hoya's net income of $331M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Hoya's price-to-earnings ratio is 29.71x while Takeda Pharmaceutical's PE ratio is 67.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hoya is 6.78x versus 1.58x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.